High tide for protides: Nucana Biomed pulls in $57M series B
Buoyed by unexpectedly early signs of robust clinical efficacy for its lead protide cancer drug Acelarin (NUC-1031), Nucana Biomed Ltd. raised $57 million in a series B round to accelerate its development and to advance several others into the clinic.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST